# **ORIGINAL ARTICLE**

# Assessment of Severity of Anxiety and Depression in Covid-19 Patients Admitted to Rawalpindi Medical University and Allied Hospitals Rawalpindi Pakistan

SADIA YASIR<sup>1</sup>, GHULAM FATIMA<sup>2</sup>, ZARNAIN UMAR<sup>3</sup>, ZONA TAHIR<sup>4</sup>, QASIM MALIK<sup>5</sup>, AZFAR MAQSOOD<sup>6</sup>, SULTAN MUHAMMAD<sup>7</sup> <sup>1</sup>Assistant Professor, <sup>3,4</sup>Senior Registrars, Department of Psychiatry, Rawalpindi Medical University, Rawalpindi

<sup>2</sup>Senior Psychologist, <sup>6</sup>Consultant Psychiatrist, <sup>6</sup>Postgradute Resident, Institute of Psychiatry, Benzir Bhutto Hospital Rawalpindi

<sup>7</sup>Assistant Professor, Department of Psychiatry, Pakistan Institute of Medical Sciences, Islamabad

Correspondence to: Sadia Yasir, Email: sadiayasir73@gmail.com, Cell: 0333-4746639

# ABSTRACT

**Objective:** To determine the prevalence of anxiety and depression among the COVID-19 infected patients. **Study design:** Descriptive cross-sectional study.

Place and Duration of Study: Rawalpindi Medical University and Allied Hospitals Covid designated wards from 1<sup>st</sup> April 2019 and 30<sup>th</sup> June 2020

**Methodology:** Hundred patients of either gender presented with Covid-19 infection were enrolled. Detailed demographics and complete medical examination was done after taking informed written consent. Those patients who fulfil the clinical criteria Hamilton rating scale for anxiety (HAMA) and Hamilton rating scale for depression (HRSD) were applied to assess the severity of anxiety and/or depression.

**Results:** There were 69 (69%) males and 31 (31%) females. Eighty two (82%) patients fall in the age range of 21 to 50 years with the mean of 38 years. There is high level of anxiety as well as depression among admitted patients suffering from COVID-19. Seventy five (75%) patients suffered from depression and 72 (72%) of patients suffered from anxiety ranging from mild to severe.

**Conclusion:** It is concluded that patients suffering from Covid-19 disease had high prevalence of depression and anxiety. **Keywords:** Covid 19, Anxiety and depression, Physical comorbidities

## INTRODUCTION

In December 2019, the first case of SARS-CoV was reported in Wuhan (China). WHO declared it a global pandemic soon after its rapid global spread on March 11, 2020. <sup>1</sup> The United Nations also warned of the risk of a global health crisis caused by the Corona virus. <sup>2</sup>

It has been reported that COVID-19 infections increase the risk of post-traumatic stress disorder, stress, and psychological distress in both patients and health care workers.Multiple factors can play a role in the development of stress, anxiety, fear, and depression in admitted patients. First, there is uncertainty regarding the treatment protocol in hospitals. Second is the rapid and devastating spread of the COVID-19 infection. A lot of people have been isolated and quarantined in their homes, and severe cases have been admitted to hospitals. Third, the course and prognosis of this viral infection are unclear, along with the sudden worsening of symptoms and deaths occurring among young patients. The fourth factor can be due to the complete and forced isolation of the infected individuals. Evidence shows that the more severe the mental health issues, the longer it will take for the patients to recover from physical illness. <sup>5</sup>

Patients who have physical illnesses are routinely screened for anxiety and depression, as the chances of having anxiety and depression with physical illnesses are relatively high. <sup>6</sup> The response of the patients to treatment is also affected by the severity of anxiety and depression.

## MATERIALS AND METHODS

This descriptive, cross-sectional study was conducted from 1<sup>st</sup> April 2020 to 30<sup>th</sup> June 2020. We included 100 patients, using consecutive sampling technique, who were hospitalized in specialized units for COVID-19 patients at RMU and Allied hospitals Rawalpindi. Patients with a positive PCR for covid-19 admitted to the hospital were included in the study and patients who were on ventilators, having a previous history of psychiatric illness and those who refused to give consent were excluded.

After the approval from ethical review committee of Rawalpindi medical university and allied hospitals (letter # 97/IREF/RMU/2020), data was collected from the diagnosed cases admitted in Allied hospitals of RMU after taking written informed consent from the patients. We collected data on the travel history if

any, the physical symptoms and comorbidities as diabetes mellitus, ischemic heart disease, hypertension, asthma, TB, COPD or any other through a pre-developed questionnaire. Study participants were also asked whether they were suffering from physical symptoms (fever, cough, shortness of breath, fatigue, sore throat, headache, myalgia, and any other symptom).

The patients were interviewed based on ICD 10 diagnostic criteria of depression and anxiety. Those patients who fulfil the clinical criteria Hamilton rating scale for anxiety (HAMA) and Hamilton rating scale for depression (HRSD) were applied to assess the severity of anxiety and/or depression. The optimal HAM-A score ranges are mild anxiety = 8-14; moderate = 15-23; severe ≥24 (scores ≤7 were considered to represent no/minimal anxiety). We used the 17 item HRSD scale with each item on the scale is scored on a 3- or 5-point scale. The scoring is as follows; not depressed: 0-7, mild (subthreshold): 8-13, moderate (mild): 14-18, severe (moderate): 19-22 and very severe (severe) >23. Data was analyzed using SPSS-16. Statistical analysis was used to ascertain correlation with a p value <0.05 considered statistically significant.

## RESULTS

Among the sample of hundred admitted COVID-19 patients 69% were males and 31% were females. 82% of the patients fall in the age range of 21 to 50 years with the mean of 38 years. Among the sample of one hundred participants, 92% had no travel history and 8% had a positive travel history. A large proportion of study participants had comorbid physical illnesses 5% had asthma,3% had COPD, 32% had Diabetes, 27% had hypertension, 14% suffered from ischemic heart disease and 4% had chronic kidney disease (Table 1).

There is high level of anxiety as well as depression among admitted patients suffering from COVID-19. 22% had mild depression, 11% have moderate depression, 13% had severe depression and 26% had very severe depression, 39% patients had severe depression (Fig. 1). 75% had anxiety ranging from mild to severe (Fig. 2).

When symptoms of anxiety and depression were considered according to comorbidities of participants , it was found that patients suffering from ischemic heart disease, diabetes mellitus and hypertension showed higher anxiety and depression as compared to patients suffering from Asthma, Chronic obstructive pulmonary disease (COPD), TB and renal failure. Among the patients suffering from hypertension 81% (22) reported symptoms of anxiety ranging from mild to severe and 77% (20) participants suffering from hypertension reported symptoms of depression ranging from mild to very severe, among patients suffering from ischemic heart disease 71% (10) of participants reported symptoms of anxiety ranging from mild to severe.

Coming to symptoms of COVID-19 admitted patients the wide range of symptoms have been observed ranging from asymptomatic infection to severe pneumonia. The most frequent symptom in current study were fever or chills 88%, cough 82%, myalgias 80% followed by headache, shortness of breath and gastrointestinal symptoms. 57% patients had positive findings on chest X-ray and chest CT scan. Out of those 57% patients 35% had depression and 36% had anxiety.

Variable	No.	%
Gender		
Male	31	31.0
Female	69	69.0
Comorbidities		
Asthma	5	5.0
COPD	3	3.0
Diabetes	32	32.0
Hypertension	27	27.0
Ischemic heart disease	14	14.0
Renal failure	4	4.0
Nil	15	15.0





Fig. 1: Overall prevalence of anxiety in patients suffering from Covid-19

Fig. 2: Overall prevalence of depression among participants suffering from Covid-19 infection

## DISCUSSION

There are significantly higher rates of anxiety symptoms (72%) and depressive symptoms (72%) as compared to a study conducted in China<sup>4</sup> having a sample of 307 patients where 18.6% were having anxiety symptoms and 13.4% were having symptoms of

depression. These high rates can be attributed to several factors including meagre resources in our current health care system, growing burden of COVID-19 infected patients and lack of information to the patients regarding treatment protocols being followed. The patients who are tested positive are disconnected from outside world and all they could interact is with a person wearing a PPE and dispensing medications. Their emotional and psychological needs are not met because of social distancing and complete isolation.

Patients and their relatives experience high levels of anxiety due to Covid-19, but frequency of depressive symptoms is low. It contrasts with the current study where almost 75% have anxiety and 72% have depression. It can be due to the presence of comorbid physical illness that our study population has, leading to increased risk of mental health issues<sup>9</sup> and to the unpredictable outcome of COVID-19 infection and loss of loved ones in the family.

In the present study, the patients suffering from medical illnesses experience more anxiety and depression especially the patients suffering from ischemic heart disease, diabetes mellitus and hypertension while the patients who had comorbid asthma, COPD, tuberculosis, and renal failure had low anxiety and depressive symptoms. Similar results have been observed in a Chinese study in which more than one third of patients had an underlying physical comorbidity and 97.2% of patients with COVID-19 had some degree of depression.<sup>10,11</sup> This study also shares similar findings where hypertension, chronic bronchitis or chronic obstructive pulmonary disease and diabetes were the three comorbidities associated with higher rates of depression and anxiety. Similar findings have been seen in studies done in other regions of the globe revealing strong association between comorbidities such as diabetes, heart diseases, chronic renal disease, obesity and COVID-19 hospitalization.12-15

Current study has few limitations such as the sample size was small. It was difficult to collect the data from isolated patients because for collection we had to communicate wearing PPE that might have increased anxiety among patients. The patients were interviewed after their COVID-19 test was positive there is a possibility that patients who chose not to participate have more depression or anxiety. No comparison was done between patients suffering from corona virus infection and those admitted other infective aetiologies that require physical distancing, so it is not possible to tell if high percentage of depression and anxiety is more prevalent in patients suffering from COVID-19.

#### CONCLUSION

The level of psychological burden in the form of increased frequency and severity of anxiety and depression in patients suffering from Corona virus infection requires serious attention to the mental health of the patients. Our health care providers need to investigate this and devise treatment protocols for the patients admitted to hospitals. Special attention should be given to the mental health of the patients suffering from COVID-19 who have coexisting physical illnesses.

#### REFERENCES

- Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020; 94:154-5.
- Kelland K. U.N. warns of global mental health crisis due to COVID-19 pandemic. Reuters 2020.
- Kam K. Mental health an emerging crisis of COVID Pandemic Webmd Health News 2020.
- Kent EE, Ornstein KA, Dionne-Odom JN. The family caregiving crisis meets an actual pandemic. J Pain Symptom Manage 2020; 60: e66-9.
- Muskin PR. Major depressive disorder and other medical illness: a two-way street. Ann Clin Psychiatry 2010; 22(4Suppl 1): S15-20.
- Schulz R, Sherwood PR. Physical and mental health effects of family caregiving. Am J Nurs 2008;108(9 Suppl):23-7.

- Dai LL, Wang X, Jiang TC, Li PF, Wang Y, Wu SJ, et al. Anxiety and depressive symptoms among COVID-19 patients in Jianghan Fangcang Shelter Hospital in Wuhan, China. PLoS One 2020;15(8):e0238416.
- Kumar P, Chaudhary R, Chhabra S, Bhalla JK. Prevalence of anxiety and depression among COVID-19 patients admitted to tertiary care hospital. Indian J Soc Psychiatry 2021;37:88-92.
- Dorman\_ilan S, Hertz-Palmor N, Brand-Gothelf A, Hasson-Ohayon I, Matalon N, Gross R, et al. Anxiety and depression symptoms in COVID-19 isolated patients and in their relatives. Front Psychiatry 2020; 11:581598.
- Zandifar A, Badrfam R, Yazdani S, Arzaghi SM, Rhimi F, Ghasemi S, et al. Prevalence and severity of depression, anxiety, stress and perceived stress in hospitalized patients with COVID-19. J Diabetes Metabolic Disorders 2020; 19(2): 1-8.
- 11. Posso M, Comas M, Román M, Domingo L, Louro J, González C, et al. Comorbidities and mortality in patients with COVID-19 aged 60

years and older in a university hospital in Spain. Arch Bronconeumol (Engl Ed) 2020; 56(11): 756-8.

- Vaughan L, Veruttipong D, Shaw JG, Levy N, Edwards L, Winget M. Relationship of socio-demographics, comorbidities, symptoms and healthcare access with early COVID-19 presentation and disease severity. BMC Infect Dis 2021;21(1):40.
- Htun YM, Win TT, Aung A, Latt TZ, Phyo YN, Tun TM, et al. Initial presenting symptoms, comorbidities and severity of COVID-19 patients during the second wave of epidemic in Myanmar. Trop Med Health 2021; 49(1):62.
- Puah SH, Young BE, Chia PY, Ho VK, Loh J, Gokhale RS, et al. Clinical features and predictors of severity in COVID-19 patients with critical illness in Singapore. Sci Rep 2021;11(1):7477.
- Parchani A, Vidhya K, Panda PK, Rawat VS, Bahurupi YA, Kalita D, et al. Fear, anxiety, stress, and depression of novel coronavirus (COVID-19) pandemic among patients and their healthcare workers: a descriptive study. Psychol Res Behav Manag 2021; 2021: 14: 1737-46.